Paper25753636
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
Seyedmousavi S and 5 others. Antimicrob Agents Chemother, 2015. Cited by 61 papers, by iCite.
Cite this record
ConductScience Library. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Papers, record 25753636. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25753636
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aspergillus fumigatus | Major topic |
| Nitriles | Major topic |
| Pyridines | Major topic |
| Triazoles | Major topic |
| Animals | |
| Aspergillosis | |
| Female | |
| Mice |
Source PubMed
References65
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19101840 | Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. | Med Mycol | 2009 | https://conductscience.org/library/papers/19101840 | PubMed |
| 2 | 19624922 | Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. | Emerg Infect Dis | 2009 | https://conductscience.org/library/papers/19624922 | PubMed |
| 3 | 18462102 | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. | Clin Infect Dis | 2008 | https://conductscience.org/library/papers/18462102 | PubMed |
| 4 | 23129729 | Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. | J Antimicrob Chemother | 2013 | https://conductscience.org/library/papers/23129729 | PubMed |
| 5 | 12501236 | Multidrug resistance in Aspergillus fumigatus. | N Engl J Med | 2002 | https://conductscience.org/library/papers/12501236 | PubMed |
| 6 | 23114773 | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23114773 | PubMed |
| 7 | 17071636 | Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. | J Antimicrob Chemother | 2006 | https://conductscience.org/library/papers/17071636 | PubMed |
| 8 | 18177225 | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. | Clin Infect Dis | 2008 | https://conductscience.org/library/papers/18177225 | PubMed |
| 9 | 21895037 | Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. | Clin Pharmacokinet | 2011 | https://conductscience.org/library/papers/21895037 | PubMed |
| 10 | 16284102 | In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. | J Antimicrob Chemother | 2006 | https://conductscience.org/library/papers/16284102 | PubMed |
| 11 | 23697829 | Azole-resistant Aspergillus fumigatus, Iran. | Emerg Infect Dis | 2013 | https://conductscience.org/library/papers/23697829 | PubMed |
| 12 | 18212101 | In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18212101 | PubMed |
| 13 | 12512185 | Aspergillosis. Pathogenesis, clinical manifestations, and therapy. | Infect Dis Clin North Am | 2002 | https://conductscience.org/library/papers/12512185 | PubMed |
| 14 | 23183435 | In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23183435 | PubMed |
| 15 | 22530880 | Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. | Expert Opin Drug Metab Toxicol | 2012 | https://conductscience.org/library/papers/22530880 | PubMed |
| 16 | 24566183 | Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24566183 | PubMed |
| 17 | 16377699 | Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16377699 | PubMed |
| 18 | 18326856 | Activity of BAL 4815 against filamentous fungi. | J Antimicrob Chemother | 2008 | https://conductscience.org/library/papers/18326856 | PubMed |
| 19 | 24002092 | Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/24002092 | PubMed |
| 20 | 21357943 | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. | J Infect Dis | 2011 | https://conductscience.org/library/papers/21357943 | PubMed |
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42394820 | Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42394820 | PubMed |
| 42212005 | Prospective study of pharmacokinetics of isavuconazole in critically ill patients undergoing continuous hemodialysis with and without acute-on-chronic liver failure. | Ann Intensive Care | 2026 | https://conductscience.org/library/papers/42212005 | PubMed |
| 42088097 | Characterization of isavuconazole pharmacokinetics and pharmacodynamics in a real-life cohort. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42088097 | PubMed |
| 42003963 | Isavuconazole in Pediatric Invasive Fungal Infections: Outcomes and Therapeutic Drug Monitoring in a Chinese Multicenter Case Series. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42003963 | PubMed |
| 38935893 | Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. | J Antimicrob Chemother | 2024 | https://conductscience.org/library/papers/38935893 | PubMed |
| 38546795 | Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions. | J Antimicrob Chemother | 2024 | https://conductscience.org/library/papers/38546795 | PubMed |
| 37971649 | Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review. | Clin Pharmacokinet | 2024 | https://conductscience.org/library/papers/37971649 | PubMed |
| 37819504 | High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/37819504 | PubMed |
| 37378040 | Therapeutic Drug Monitoring of Isavuconazole: Lessons Learnt from a Real-life Setting in a Tertiary Care Center in India. | Indian J Crit Care Med | 2023 | https://conductscience.org/library/papers/37378040 | PubMed |
| 36991227 | A Hybrid Algorithm Combining Population Pharmacokinetic and Machine Learning for Isavuconazole Exposure Prediction. | Pharm Res | 2023 | https://conductscience.org/library/papers/36991227 | PubMed |
| 36314941 | In Vitro Susceptibilities of Worldwide Isolates of Intrapulmonary Aspergillus Species and Important Candida Species in Sterile Body Sites against Important Antifungals: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2017-2020. | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/36314941 | PubMed |
| 35812838 | Antifungal Resistance and the Role of New Therapeutic Agents. | Curr Infect Dis Rep | 2022 | https://conductscience.org/library/papers/35812838 | PubMed |
| 35109772 | Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance. | Emerg Microbes Infect | 2022 | https://conductscience.org/library/papers/35109772 | PubMed |
| 34959380 | Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles? | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34959380 | PubMed |
| 34035866 | Aspergillus fumigatus and aspergillosis: From basics to clinics. | Stud Mycol | 2021 | https://conductscience.org/library/papers/34035866 | PubMed |
| 33782009 | Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33782009 | PubMed |
| 33396870 | Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. | J Fungi (Basel) | 2020 | https://conductscience.org/library/papers/33396870 | PubMed |
| 32201545 | Extrapolating Antifungal Animal Data to Humans - Is it reliable? | Curr Fungal Infect Rep | 2020 | https://conductscience.org/library/papers/32201545 | PubMed |
| 31767725 | Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/31767725 | PubMed |
| 31717953 | RgsA Attenuates the PKA Signaling, Stress Response, and Virulence in the Human Opportunistic Pathogen Aspergillus fumigatus. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31717953 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25753636
GET https://conductscience.org/api/papers/v1/25753636/references?page=2